Our platform enables us to efficiently find drug candidates with desirable properties. Our medicines target the genetic determinants of disease at the level of RNA or DNA. These genetic diseases are mediated by altered molecular phenotypes, such as transcription, splicing, translation and protein binding. Predicting those alterations is our core competency. The oligonucleotide therapeutic design space includes tens of billions of compounds, but our platform makes it possible to search this space efficiently.
On-target and genome-wide off-target effect data is produced for every compound identified using our platform. That data is then fed back, closing the loop. We even test compounds that push the boundaries of what’s possible. This means that our platform is getting better at identifying extraordinary targets and compounds, and is doing so faster.
Our platform incorporates the most advanced biological knowledge, is driven by the most powerful automation technologies, and is built using proprietary as well as public datasets. Our work has appeared in Science, Nature, Nature Genetics, Nature Medicine, Nature Methods, Proceedings of the IEEE, NIPS, Bioinformatics, RECOMB and ISMB. When other scientists and engineers publish a discovery, we evaluate it and if appropriate rapidly incorporate it into our platform.
Smart drug design is about predicting outcomes up front. That's what our AI platform does best, and Saturn is the proof.
In Project Saturn, we're using our platform to evaluate over 69 billion molecules against 1 million targets, in silico, to generate a library of 1000 compounds that are experimentally verified to manipulate cell biology as intended. Think of it as a toolkit for controlling cell biology along crucial pathways, rapidly unlocking therapies with greater potential.
Our scientists regularly publish in their fields' most influential peer-reviewed journals. Here is a selection of our contributions.